OLR1 and Huntington disease: Likewise, rosuvastatin and/or sarpogrelate treatment did reverse the increased expression level of LOX-1, which was observed in mice from the ApoE−/− HD group, indicating excessive proinflammatory release, endothelial dysfunction, and other active immune responses in these mice (∗P < 0.05 vs. ApoE−/− HD; #P < 0.05 vs. ApoE−/− HD+R) (Figures 3(b) and 3(c)).